Methods, compositions, and kits are provided for imaging a polypeptide of interest. Methods, compositions, and kits are also provided for site-specific transcriptional regulation of one or more genetic elements.

Methods, compositions, and kits are provided for imaging a polypeptide of interest. Methods, compositions, and kits are also provided for site-specific transcriptional regulation of one or more genetic elements.

The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. The microbe-targeting or microbe-binding molecules can comprise a microbe surface-binding domain linked to a portion of an Fc region. Further, the microbe-targeting molecules can be conjugated to substrate (e.g., a magnetic particle) to form a microbe-targeting substrate. Such microbe-targeting molecules and/or substrates and the kits comprising the same can be used in various applications, such as diagnosis and/or treatment of an infection caused by microbes. Moreover, the microbe-targeting molecules and/or substrates can be easily regenerated after use.

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. The microbe-targeting or microbe-binding molecules can comprise a microbe surface-binding domain linked to a portion of an Fc region. Further, the microbe-targeting molecules can be conjugated to substrate (e.g., a magnetic particle) to form a microbe-targeting substrate. Such microbe-targeting molecules and/or substrates and the kits comprising the same can be used in various applications, such as diagnosis and/or treatment of an infection caused by microbes. Moreover, the microbe-targeting molecules and/or substrates can be easily regenerated after use.

Described are immunogenic compositions comprising a non-naturally occurring pan-fungal Kex peptide, and methods of using such compositions for the treatment or prevention of infection and/or diseases associated with fungal pathogens (e.g., Pneumocystis, Aspergillus, Candida, or Cryptococcus) in the subject. Also provided are compositions and kits for detecting or quantifying the presence of antibodies directed against a non-naturally occurring pan-fungal Kex peptide in a subject.

Described are immunogenic compositions comprising a non-naturally occurring pan-fungal Kex peptide, and methods of using such compositions for the treatment or prevention of infection and/or diseases associated with fungal pathogens (e.g., Pneumocystis, Aspergillus, Candida, or Cryptococcus) in the subject. Also provided are compositions and kits for detecting or quantifying the presence of antibodies directed against a non-naturally occurring pan-fungal Kex peptide in a subject.

A problem to be solved is to perform an immunoassay method for BG in a biological sample having a sensitivity equivalent to and a reactivity similar to a Limulus amebocyte lysate reagent. The problem can be solved by an immunoassay method for β-D-glucan in a biological sample, comprising assaying β-D-glucan in the biological sample by using a monoclonal antibody binding to (1.fwdarw.3)-β-D-glucan having a degree of polymerization of 4.

This invention relates to recombinant human antibody molecules for use in a method of treatment of Acinetobacter infection. The antibodies bind Acinetobacter antigens, for example from Acinetobacter spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.